Maxcyte (MXCT) Cash from Investing Activities (2020 - 2026)
Maxcyte (MXCT) posted quarterly Cash from Investing Activities of $2.7 million for Q1 2026, down 72.13% year-over-year from $9.5 million in Q1 2025, and down 72.55% quarter-over-quarter from $9.7 million in Q4 2025.
Maxcyte (MXCT) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Maxcyte (MXCT) has reported Cash from Investing Activities for 7 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 72.13% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $19.1 million (down 38.22% YoY), while the FY2025 annual figure was $25.9 million, up 274.13% from the prior year.
- Cash from Investing Activities declined to $2.7 million in Q1 2026 per MXCT's latest filing, from $9.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $194.8 million in Q1 2022 and bottomed at -$131.9 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged $3.9 million across 5 years, with a median of $2.8 million in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 1141.41% in 2022 and fell as far as 257.12% in 2022.
- Maxcyte's Cash from Investing Activities stood at -$27.1 million in 2022, then soared by 84.72% to -$4.1 million in 2023, then surged by 59.77% to -$1.7 million in 2024, then jumped by 681.14% to $9.7 million in 2025, then slumped by 72.55% to $2.7 million in 2026.
- Business Quant data shows MXCT's Cash from Investing Activities at $2.7 million in Q1 2026, $9.7 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.52 Bn | 193.92 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 127.77 Bn | 124.29 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 119.02 Bn | 109.80 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 73.50 Bn | 72.96 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.87 Bn | 31.76 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.39 Bn | 23.07 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.07 Bn | 22.58 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Maxcyte | 146.35 Mn | 146.35 Mn | 5.60 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Mn |
| Jun 30, 2026 | 6.57 Mn |
| Mar 31, 2026 | 2.66 Mn |
| Mar 31, 2026 | 2.66 Mn |
| Dec 31, 2025 | 9.68 Mn |
| Dec 31, 2025 | 9.68 Mn |
| Sep 30, 2025 | 5.19 Mn |
| Sep 30, 2025 | 5.19 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Dec 31, 2024 | -1.67 Mn |
| Dec 31, 2024 | -1.67 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 19.39 Mn |
| Jun 30, 2024 | 19.39 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Mar 31, 2024 | -14.40 Mn |